Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency

Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency

Abstract In this analysis we describe the effectiveness of first-line ibrutinib in 747 patients with chronic lymphocytic leukemia (CLL) and TP53 aberrations in a nationwide study with a 100% capture of patients who received the study drug. Median age was 71 years (range 32–95). An estimated treatmen...

Full description

Bibliographic Details
Main Authors: Gian Matteo Rigolin, Pier Paolo Olimpieri, Valentina Summa, Simone Celant, Lydia Scarfò, Lucia Tognolo, Maria Pia Ballardini, Antonio Urso, Mariarosaria Sessa, Silvia Gambara, Francesca Cura, Monica Fortini, Paolo Ghia, Antonio Cuneo, Pierluigi Russo
Format: Article
Language:English
Published: Nature Publishing Group 2023-06-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-023-00865-z

Internet

https://doi.org/10.1038/s41408-023-00865-z

Similar Items